Work

Abstract A004: HER2 cancer vaccine phase I clinical trial shows clinical benefit in 54% of evaluable patients

Year: 2019

Type: conference-abstract

Source: Cancer Immunology Research

DOI: 10.1158/2326-6074.cricimteatiaacr18-a004

Authors: Jay A. Berzofsky, Lauren V. Wood, Hoyoung Maeng, Jane Trepel, David Stroncek, John C. Morris

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, National Institutes of Health Clinical Center, University of Cincinnati

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2912404450

Cites:

Cited by: 2

Related to: 10